The first clinical consensus statement for managing multiple sclerosis (MS) in Australia and New Zealand has been released, ...

Cosmos Health Inc. ("Cosmos Health" or the "Company")(NASDAQ:COSM) , a diversified, vertically integrated global healthcare ...

Since being diagnosed with multiple sclerosis (MS) in 2018, Blair has emerged as a fierce advocate for those living with ...

Migraine may be a symptom of prodromal multiple sclerosis (MS), as the risk for migraine gradually increased closer to the onset of MS symptoms. Women with multiple sclerosis (MS) show increased risk ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Cosmos Health (COSM) announced the filing of a patent application for treatment for multiple sclerosis, a disabling autoimmune disorder ...

Neuraxpharm Ireland, part of Neuraxpharm Group, a leading European speciality pharmaceutical company focused on the treatment ...

Scott, an internationally recognized neurologist and leader in multiple sclerosis (MS) research and clinical care, has been awarded the 2024 MS Research Award by MS Australia.

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

Multiple sclerosis (MS) causes neurological symptoms ... Ocrelizumab (Ocrevus) is the newest infusion treatment for MS. It was approved by the FDA in 2017. It’s the first drug used to treat ...